BioMarker's proprietary platform is based on identifying genes and their protein products involved in aging and age-related diseases in mice and humans. By identifying statistically significant variability in gene expression levels in models in which aging has been slowed, such as caloric restriction (CR) and dwarf mice, we are earmaking biomarkers for the development of new age-defying and age-related disease therapies.
To Identify biomarkers involved in aging and age-related diseases, we are applying two methods. First, DNA microarrays (gene chips) are used to measure levels of transcription of all known genes. Second, the presence of secreted protein products in the bloodstream is measured by mass spectrometry.
Besides characterizing gene and protein biomarkers, we are using these technologies to identify compounds that reproduce the beneficial, age-defying effects of calorie restriction (CR). BioMarker's platform identifies genes, targets, networks and mechanisms that are responsible for the effects of CR. Compounds can be screened quickly to determine whether they can be developed as CR mimetics – with broad-spectrum disease prevention and health maintenance effects.
BioMarker Database BioMarker has established a proprietary database containing gene expression profiles of animals on both long-term and short-term calorie restriction. Our database also includes profiles of gene expression levels related to nutraceuticals under development, as well as other compounds tested by BioMarker.
BioMarker's unique approach is protected by several patents, issued and pending, including the first issued U.S. patent in the field: Interventions to mimic the effects of calorie restriction, US Patent 6,406,853, June 18, 2002.
